4-(4-氯苯甲酰基)哌啶盐酸盐 | 55695-51-7

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酮
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-(4-氯苯甲酰基)哌啶盐酸盐
• 中文别名: 4-(p-氯苯甲酰)哌嗪盐酸盐；(4-氯苯基)(4-哌啶)甲酮盐酸盐
• 英文名称: 4-(4-chlorobenzoyl)piperidine hydrochloride
• 英文别名: (4-chloro-phenyl)-piperidin4-yl-methanone hydrochloride；(4-chlorophenyl)-piperidin-4-ylmethanone;hydrochloride
• CAS: 55695-51-7
• 化学式: C₁₂H₁₄ClNO*ClH
• mdl: MFCD00053028
• 分子量: 260.163
• InChiKey: LZUYKOBTHSPKED-UHFFFAOYSA-N

物化性质

• 熔点：
  238-239°C
• 溶解度：
  溶于甲醇、水
• 稳定性/保质期：

  如果按照规格正确使用和储存，则不会分解，目前没有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  2.24
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  29.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将贮藏器保持密封状态，并存放在阴凉、干燥处。同时，确保工作环境具有良好的通风或排气设施。

SDS

Name:	(4-Chlorophenyl)(4-piperidyl)methanone hydrochloride 95+% Material Safety Data Sheet
Synonym:	4-(4-Chlorobenzoyl)piperidine hydrochlorid
CAS:	55695-51-7

Section 1 - Chemical Product MSDS Name:(4-Chlorophenyl)(4-piperidyl)methanone hydrochloride 95+% Material Safety Data Sheet
Synonym:4-(4-Chlorobenzoyl)piperidine hydrochlorid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
55695-51-7	(4-Chlorophenyl)(4-piperidyl)methanone	95+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 55695-51-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 238 - 239 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H15Cl2NO
Molecular Weight: 260

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, bases, acid chlorides.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 55695-51-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(4-Chlorophenyl)(4-piperidyl)methanone hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 55695-51-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 55695-51-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 55695-51-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

(4-氯苯基)(4-哌啶)甲酮盐酸盐是一种有机合成中间体和医药中间体，广泛应用于实验室研发及化工生产的各种过程。

反应信息

• 作为反应物：
  描述：

  4-(4-氯苯甲酰基)哌啶盐酸盐 在 ammonium acetate 、 sodium cyanoborohydride 、 三乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 36.0h， 生成 4-[amino(4-chlorophenyl)methyl]piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2007/125320

  摘要：

  公开号：
• 作为产物：
  描述：

  1-BOC-4-(4-氯苯甲酰)哌啶 在 盐酸 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 5.0h， 以100%的产率得到4-(4-氯苯甲酰基)哌啶盐酸盐
  参考文献：
  名称：

  [EN] MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS
  [FR] INHIBITEURS MITOCHONDRIALES POUR LE TRAITEMENT DE TROUBLES PROLIFÉRATIFS

  摘要：

  该发明提供了式(I)的化合物或其药学上可接受的盐，其中环A代表A-I、A-II或A-III基团。Al代表-C(R4a)(R4a)-、-C(R4a)= -N(R4b)-、-N= -O-或-S-；A2代表-C(R4c)(R4c)-、-C(R4c)=或-0-；A3代表-C(R4c)(R4c)-、-C(R4c)=或-0-；A4代表-C(R4a)(R4a)-、-C(R4a)= -N= -O-或-S-；A5代表-C(R4a)(R4a)-、-C(R4a)= -N(R4b)-、-N= -O-或-S-；A6代表-C(R4c)(R4c)-或-C(R4c)=；A7代表-C(R4a)(R4a)-、-C(R4a)= -N= -O-或-S-；A8代表-C(R4a)(R4a)-、-N(R4b)-、-O-或-S-；A9代表-C(R4c)(R4c)-或-0-；A10代表-C(R4c)(R4c)-或-0-；A11代表-C(R4c)(R4c)-或-0-；A12代表-C(R4a)(R4a)-、-O-或-S-；其中A-I基团、A-II基团和A-III基团不含相邻的氧原子、相邻的氧和硫原子或相邻的氧和氮原子，或从N-C-N、N-C-S、S-C-S、O-C-N、O-C-O和O-C-S组成的基团中选择的基团，其中在每种情况下，N-C-N、N-C-S、S-C-S、O-C-N、O-C-O和O-C-S基团中的碳原子是饱和的；B1、B2、B3和B4分别代表C(R3)或N，其中B1、B2、B3和B4中最多有两个代表N；n为1或2；R1、R2、R3、R4a、R4b和R4c如索引中所定义，以及使用这些化合物治疗增殖性疾病，特别是癌症的方法。

  公开号：

  WO2019072978A1

文献信息

• [EN] 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS<br/>[FR] DERIVES DE PIPERIDINE 1,4 DISUBSTITUEE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE 11-BETAHSD1
  申请人：ASTRAZENECA AB

  公开号：WO2004033427A1

  公开（公告）日：2004-04-22

  The use of a compound of formula (I) in the manufacture of a medicament for use in the inhibition of 11βHSD1 is described.

  使用式(I)的化合物制造用于抑制11βHSD1的药物。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2004011410A1

  公开（公告）日：2004-02-05

  Compounds of formula (I):wherein variable groups are as defined within; for use in the inhibition of 11βHSD1 are described.

  式(I)的化合物：其中变量基团如定义内；用于抑制11βHSD1。
• <i>N,N</i>-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide:  A Novel, Exceptionally Selective, Potent δ Opioid Receptor Agonist with Oral Bioavailability and Its Analogues
  作者：Zhong-Yong Wei、William Brown、Bryan Takasaki、Niklas Plobeck、Daniel Delorme、Fei Zhou、Hua Yang、Paul Jones、Lars Gawell、Helene Gagnon、Ralf Schmidt、Shi-Yi Yue、Chris Walpole、Kemal Payza、Stephane St-Onge、Maryse Labarre、Claude Godbout、Andrea Jakob、Joanne Butterworth、Augustus Kamassah、Pierre-Emmanuel Morin、Denis Projean、Julie Ducharme、Edward Roberts

  DOI：10.1021/jm000229p

  日期：2000.10.1

  and exhibit excellent selectivity for the delta opioid receptor as full agonists. 6a, the simplest structure in the class, exhibited an IC(50) = 0.87 nM for the delta opioid receptors and extremely high selectivity over the mu receptors (mu/delta = 4370) and the kappa receptors (kappa/delta = 8590). Rat liver microsome studies on a selected number of compounds show these olefinic piperidine compounds

  描述了新型δ阿片受体激动剂N，N-二乙基-4-（苯基哌啶丁-4-亚甲基甲基）苯甲酰胺（6a）及其类似物的设计，合成和药理学评价。这些化合物通过用含有环外碳碳双键的哌啶环取代哌嗪环而正式衍生自SNC-80（2），发现它们以高亲和力结合，并且对作为完全激动剂的δ阿片受体表现出优异的选择性。图6a是同类中最简单的结构，其δ阿片受体的IC（50）= 0.87 nM，对mu受体（mu / del = 4370）和kappa受体（kappa / delta = 8590）的选择性极高。对选定数量的化合物进行的大鼠肝微粒体研究显示，这些烯属哌啶化合物（6）比SNC-80稳定得多。这一系列新颖的化合物似乎以与SNC-80类似的方式与δ阿片受体相互作用，因为它们表现出相似的SAR。基于二苯甲基醇的脱水（7）和乙烯基溴的Suzuki偶联反应（8），已经建立了两种合成这些化合物的通用方法，据报道。
• Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors
  申请人：Gobbi Luca

  公开号：US20070197531A1

  公开（公告）日：2007-08-23

  The present invention relates to compounds of the general formula as dual modulators of the 5-HT 2a and D 3 receptors useful against CNS disorders, wherein A, R 1 , R 2 , n, p, q and r are as defined in the specification.

  本发明涉及一般公式的化合物，作为5-HT2a和D3受体的双重调节剂，用于对抗中枢神经系统疾病，其中A、R1、R2、n、p、q和r的定义如规范中所述。
• Compounds
  申请人：AstraZeneca AB

  公开号：US06518286B1

  公开（公告）日：2003-02-11

  The invention provides compounds of general formula (I) wherein: R1 represents optionally substituted, C1-C12 alkyl or optionally substituted 3- to 10-membered saturated or unsaturated ring system comprising up to two ring carbon atoms that form carbonyl groups and comprising up to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulfur; m is 0-1; Q represents OCH2, C1-C4 alkylene or C2-C4 alkenylene; T represents C(O)NH, or when m is 0, T may additionally represent a bond or NH, or when m is 1 and Q represents C1-C4 alkylene, T may additionally represent NH; n is 1-4; each R2 and R3 independently represents H or C1-C4 alkyl; V represents N, and W represents N or CH; X represents O, C(O), CH(OH), SO2, NH or N(C1-C6 alkyl), provided that when W represents N, then X represents either C(O) or SO2 and when W represents CH, then X is other than SO2; R4 represents optionally substituted phenyl; R5 and R6 each independently represent H, C1-C6 alkyl or hydroxyC1-C6 alkyl, or R5 and R6 together with the nitrogen atom to which they are attached form a 4- to 7-membered saturated heterocyclic ring; R7 and R8 each independently represent H or C1-C6 alkyl; and R9 represents OH or —NR7R8; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  该发明提供了通式（I）的化合物，其中：R1代表可选择取代的C1-C12烷基或可选择取代的3-至10-成员饱和或不饱和环系统，包括最多两个环碳原子形成羰基，并包括最多4个环杂原子，独立选择自氮、氧和硫；m为0-1；Q代表OCH2，C1-C4烷基或C2-C4烯基；T代表C(O)NH，或当m为0时，T还可以表示键或NH，或当m为1且Q代表C1-C4烷基时，T还可以表示NH；n为1-4；每个R2和R3独立表示H或C1-C4烷基；V表示N，W表示N或CH；X表示O，C(O)，CH(OH)，SO2，NH或N(C1-C6烷基)，但当W表示N时，X表示C(O)或SO2，当W表示CH时，X不是SO2；R4代表可选择取代的苯基；R5和R6各自独立表示H，C1-C6烷基或羟基C1-C6烷基，或R5和R6与它们连接的氮原子一起形成4-至7-成员饱和杂环；R7和R8各自独立表示H或C1-C6烷基；R9表示OH或—NR7R8；它们的制备方法，含有它们的药物组合物以及它们在治疗中的用途。